#patient advocacy
9 articles with this tag
Pharma CEO Time Management: Governing Patient Advocacy and Disease Community Engagement
How pharma CEOs govern patient advocacy relationships, disease community engagement, and patient-centered evidence that improves regulatory and payer outcomes.
How Pharma CEOs Manage Time for Patient-Reported Outcome Programs
How pharma CEOs govern patient-reported outcome (PRO) measurement programs in clinical trials and post-marketing studies, including instrument selection.
How Rare Pediatric Disease Pharma CEOs Manage Time
Rare pediatric disease pharma CEO time management: FDA designations, pediatric KOL relationships, compassionate use programs.
Patient Advocacy Engagement Pharma: How CEOs Allocate Time to Build Productive Partnerships
Time allocation strategies for pharma CEOs building genuine patient advocacy partnerships that accelerate drug development and strengthen market access.
Rare Disease Patient Journey Leadership: How CEOs Invest Time to Understand and Advocate
How CEOs of rare disease companies invest time understanding patient journeys and building advocacy that accelerates development and improves outcomes.
Time Management for Healthcare Advocacy Nonprofit CEOs
How CEOs of healthcare advocacy nonprofits manage time across patient advocacy programs, pharmaceutical partnerships, health policy advocacy.
Time Management for Pharma CEOs Managing Compassionate Use Programs
Pharma CEO compassionate use expanded access time management: individual patient IND governance, right-to-try compliance, access capacity.
Time Management for Pharma CEOs Navigating Drug Pricing Policy Debates
Pharma CEO drug pricing policy time management: IRA negotiations, government affairs, congressional testimony, patient advocacy.
Time Management for Rare Disease Pharma CEOs
Time management strategies for rare disease pharma CEOs managing patient advocacy, natural history studies, FDA Breakthrough designation.